



The COMPLAINTS After Stroke (COMPAS) study: protocol for a Dutch cohort study on post-stroke subjective cognitive complaints

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003599
Article Type:	Protocol
Date Submitted by the Author:	15-Jul-2013
Complete List of Authors:	van Rijsbergen, Marielle; Tilburg University, Department of Cognitive Neuropsychology Mark, Ruth; Tilburg University, Department of Cognitive Neuropsychology de Kort, Paul; St. Elisabeth Hospital, Neurology Sitskoorn, Margriet; Tilburg University, Department of Cognitive Neuropsychology
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Patient-centred medicine, Rehabilitation medicine
Keywords:	Stroke < NEUROLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 1 **The COMPlaints After Stroke (COMPAS) study: protocol for a Dutch**
5
6 2 **cohort study on post-stroke subjective cognitive complaints**
7
8
9 3

10
11 4 Marielle W.A. van Rijsbergen,¹ Ruth E. Mark,^{1*} Paul L. M. de Kort,² Margriet M. Sitskoorn¹
12
13 5

14
15
16 6 ¹ Department of Cognitive Neuropsychology, Centre of Research on Psychology in Somatic
17 7 diseases (CoRPS), Tilburg University, Tilburg, The Netherlands.

18
19 8 ² Department of Neurology, St. Elisabeth Hospital, Tilburg, The Netherlands.
20
21 9

22
23
24
25 10 ***Corresponding author**

26
27 11 Ruth E. Mark: Department of Cognitive Neuropsychology, Centre of Research on Psychology
28 12 in Somatic diseases (CoRPS), Tilburg University, PO Box 90153, 5000 LE Tilburg, The
29 13 Netherlands.
30
31 14

32
33 15 Tel.: **31 13 466 2562

34
35 16 Fax: **31 13 466 2067

36
37 17 r.e.mark@tilburguniversity.edu
38
39 18

40
41
42
43
44 19 **Short title:** Study protocol: post-stroke subjective cognitive complaints

45
46 20 **Keywords:** stroke; subjective cognitive complaints; objective cognitive impairment; quality of
47 21 life; longitudinal; protocol.
48
49 22

50
51
52
53 23 **Word count: 2861**
54
55 24

1
2
3
4 **1 ABSTRACT**

5
6 **2 Background:** Whereas many studies have assessed post-stroke objective cognitive impairment,
7
8 only a few have evaluated patients' Subjective Cognitive Complaints (SCC). Although these
9
10 SCC are found to be common in both the early and chronic phase after stroke, knowledge about
11
12 their risk factors, course over time, differences with healthy controls, and their diagnostic
13
14 relevance is limited. The aim of the COMPlaints After Stroke (COMPAS) study is therefore to
15
16 determine the possible risk factors, prognosis, time course, and predictive value of SCC in the
17
18 first two years after stroke.
19
20

21
22 **9 Methods and design:** A prospective cohort study is conducted in which patients are compared
23
24 to non-stroke controls at 3, 6, 12, and 24 months after stroke. Approximately 300 patients are
25
26 recruited from the stroke units of 3 hospitals in The Netherlands, while 300 controls are sought
27
28 among the relatives and social networks of participants. A wide range of subjective and
29
30 objective variables is assessed in both groups using interviews, questionnaires, and
31
32 neuropsychological assessment. The primary outcomes include SCC and objective cognitive
33
34 impairment, whereas secondary outcome are quality of life, subjective recovery, and daily life
35
36 functioning.
37
38

39
40 **17 Ethics and dissemination:** The study is being carried out in agreement with the Declaration of
41
42 Helsinki and the medical Research Involving Human Subjects Act. The protocol has been
43
44 approved by the medical ethics committees of the participating centres and all participants give
45
46 written informed consent. The results will be published in peer-reviewed journals and
47
48 disseminated to both the medical society and general public.
49

50
51 **22 Discussion:** The COMPAS study is the first to systematically evaluate post-stroke SCC in a
52
53 prospective longitudinal design, taking a wide range of subjective and objective variables into
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 account. The results obtained can be used to accurately inform patients and their families, and
2 to develop patient tailored intervention programmes to ultimately improve stroke patient care.
3

For peer review only

1 ARTICLE SUMMARY

2 Article focus:

- 3 • The aim of the COMPlaints After Stroke (COMPAS) study is to determine the possible risk
4 factors, prognosis, time course, and predictive value of SCC on future cognitive functioning
5 and quality of life within the first 2 years after stroke.
- 6 • It will also evaluate whether and how these aspects differ between stroke patients and non-
7 stroke controls.

9 Key messages:

- 10 • This study will determine how post-stroke SCC are related to demographic and clinical
11 characteristics, objective cognitive functioning, subjective stroke recovery, fatigue, mood,
12 stress, personality, quality of life, and daily life functioning.
- 13 • This knowledge and insight into post-stroke SCC allows clinicians to more accurately
14 inform patients and their proxies, to choose the most appropriate treatment, and to develop
15 patient tailored intervention programmes, thereby improving stroke patient-centred care.

17 Strengths and limitations:

- 18 • The strength of this study is that it is the first prospective cohort study on SCC in stroke
19 patients, systematically evaluating both patients and controls at multiple assessments, while
20 at the same time a wide range of subjectively and objectively measured variables are taken
21 into account.
- 22 • A limitation is that the most serious affected patients are unable to participate in the study.
23 This may reduce the generalizability of the results to the stroke population as a whole.

1 BACKGROUND

2 Post-stroke cognitive impairment is common after stroke and can be evaluated either
3 objectively, using neuropsychological tests (i.e. Objective Cognitive Performances; OCP), or
4 subjectively, using interviews, or self-report questionnaires (i.e. Subjective Cognitive
5 Complaints; SCC). To date, the majority of the studies on post-stroke cognitive sequelae have
6 focused on OCP without also evaluating patients' SCC. However, individuals' performances in
7 test situations do not always correspond to those in daily life and vice versa.[1 2] Evaluating
8 one can therefore not be used to draw conclusions about the other.

9 In a recent systematic review, we found that SCC are common in both the early and the
10 chronic phase after stroke, with prevalence rates varying between 28.6% and 92.0%.[3]
11 Complaints about memory, mental speed, and concentration are found to be the most
12 commonly reported. One of the main problems among these studies is however that there is no
13 'gold standard' to define and measure SCC, resulting in heterogenic findings. In our review we
14 suggested that it is important to differentiate between *content* of SCC (SCCc) and *worrying*
15 about SCC (SCCw), as these are two different concepts.[3] The first focuses on the specific
16 cognitive difficulties respondents say they experience, while the second indicates whether
17 participants find them worrisome, irritating, and whether they say they hinder daily life. A few
18 studies have made this distinction so far. [2 4 5] However, the majority of research on post-
19 stroke SCC has evaluated SSCc and not SSCw, probably without being aware of the difference
20 between these aspects of SCC.[3]

21 Furthermore, we found that post-stroke SCC tend to increase over time, and that there is
22 moderate agreement between patients and their proxies on prevalence and severity of patients'
23 SCC. [3] SCC were also found to be inconsistently associated with demographic and clinical
24 characteristics, current depressive symptoms and OCP,[3] but 2 studies showed that post-stroke

1 SCC may predict future emotional and cognitive decline.[5 6] However, most of the research
2 on SCC after stroke carried out so far is limited in that: unvalidated methods for assessing SCC
3 have been used, there was no non-stroke control group, and the focus was on a specific
4 subsample of stroke patients (e.g. home-living patients only), thereby impairing
5 generalizability of the results. While SCC are common among stroke patients, knowledge about
6 the following aspects is only limited or practically non-existent: the risk profile for developing
7 SCC; their course over time; their impact on Quality of Life (QOL), subjective recovery, and
8 Activities in Daily Life (ADL) functioning; and their prognostic implications.

9 In the general non-stroke population however, SCC have been more frequently
10 evaluated, in particular memory related SCC reported by the elderly. [7 8] Factors found to be
11 associated with these complaints include: demographic characteristics (higher age, women,
12 lower education), psychological distress, somatic complaints, personality traits (neuroticism in
13 particular), and vascular risk factors.[7-11] They are furthermore thought to be clinically
14 relevant in this group because of their association with an increased health care consumption, a
15 reduced QoL, current OCP (this link is not always found), and their predictive value for future
16 cognitive decline.[7 8 12] Whether this also applies to post-stroke SCC is unknown. More
17 systematic research is therefore needed to gain further knowledge about SCC among stroke
18 survivors, to be able to accurately inform patients and their relatives, to develop adequate
19 treatment programmes, and ultimately improve post-stroke care.

20 We therefore designed the **COMPlaints After Stroke (COMPAS)** study in which we
21 have 4 main aims, including:

- 22 • Determine the prevalence, profile and course over time of SCCc and SCCw.
- 23 • Identify the risk profile for developing SCC.
- 24 • Evaluate their predictive value for future cognitive functioning.

- 1
- 2
- 3
- 4 • Determine the effect of SCC on QoL, subjective recovery, and ADL functioning.
- 5
- 6 Here we describe the design and protocol of the COMPAS study, which is the first prospective
- 7
- 8 cohort study of SCC in stroke patients, evaluating both patients and controls, while at the same
- 9
- 10
- 11 time a wide range of variables is taken into account.
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

1 METHODS AND ANALYSIS

2 Design

3 A multicentre, prospective cohort study of stroke patients and controls is performed. We started
4 in 2009 and the final measurements will be made in 2014. Patients are evaluated 5 times,
5 starting at the clinical phase (T0), followed by an assessment at 3 months (T1), 6 months (T2),
6 1 year (T3), and 2 years (T4) after stroke. Controls are seen at the same time intervals, starting
7 at T1.

9 Study population

10 Stroke patients are recruited consecutively from the stroke units of 3 hospitals in The
11 Netherlands, including the St.Elisabeth and TweeSteden Hospitals in Tilburg, and the Maxima
12 Medical Centre in Veldhoven. The control group consists of a sample from the non-stroke
13 general population and is recruited among the relatives and the social networks of participants
14 in the COMPAS study. Spouses of stroke patients are excluded from the control group since
15 these people are at a higher risk of having physical, cognitive and psychosocial problems
16 themselves due to the fact that their partner has suffered a stroke.[13 14]

18 *Inclusion criteria:*

- 19 • Clinical diagnosis of a first or recurrent ischemic or hemorrhagic stroke (for patients
20 only).
- 21 • At least 18 years old (no upper age limit).

23 *Exclusion criteria:*

- 24 • Pre-existent health problems interfering with cognitive functioning, including:

- 1 ○ Cognitive decline (as defined by a score > 3.6 on the short version of the
- 2 Informant Questionnaire on Cognitive Decline in the Elderly; IQCODE).[15]
- 3 ○ A recent history of severe psychopathology (e.g. suicide attempts, alcohol- or
- 4 drug abuse, diagnosed personality or mood disorders).
- 5 ○ Severe physical co-morbidity (e.g. malignant diseases, progressive neurological
- 6 conditions).
- 7 • Severe communication difficulties (e.g. insufficient understanding of the Dutch
- 8 language, severe aphasia, blindness, or deafness).

10 **Procedure**

11 Eligible patients receive oral and written information about the study from their treating
12 physician during the clinical phase (T0). Demographic and clinical characteristics are
13 documented and patients are scheduled for the first assessment 3 months after stroke (T1),
14 during which written informed consent is obtained for inclusion to be definite. Subjects
15 acknowledge that they have the intention to complete all 4 assessments, and that they are
16 allowed to end their participation at any time. For the follow-up assessments (T2 – T4), patients
17 are informed by letter and telephone and invited to participate after which an appointment is
18 scheduled.

19 Potential controls receive oral and written information about the study from the
20 researcher after which they are asked to participate in the study. The rest of the procedure is the
21 same as that for the patient group.

22 The assessments are administered in a standardized way by trained neuropsychologists
23 and take place at the participating hospitals, or when this is not possible, at the participants'
24 home or residence (e.g. rehabilitation centre).

1 **Measures**

2 Tables 1 and 2 give an overview of the variables assessed and instruments used at each time
3 point.

4 *Outcomes*

5 Primary outcomes of the COMPAS study are SCC and OCP. To measure SCC, 2 instruments
6 are used, namely: the Dutch version of the Cognitive Failures Questionnaire (CFQ)[16 17] and
7 the Checklist for Cognitive and Emotional consequences following stroke (CLCE-24).[5] The
8 CFQ focuses on SCCc and asks subjects to rate 25 items on the frequency of cognitive slips
9 and errors in daily life on a five-point Likert scale ranging from 0 (never) to 4 (very often).
10 SCCw is evaluated by four additional general questions regarding the subjective increase of
11 complaints over time, the degree to which these hinder daily life, are annoying, and are a
12 source of concern. Each of these extra items is rated on a scale ranging from 1 (not at all) to 5
13 (extremely).

14 The CLCE-24 is a structured clinical interview developed more recently to evaluate
15 both SCCc and SCCw among stroke survivors.[5] It consists of 13 items concerning cognitive
16 complaints and 9 items addressing emotional and behavioural complaints. Each item is rated on
17 presence and severity, and scored as 0 (no complaint), 1 (doubtful), 2 (complaint present, but
18 not disturbing or annoying), or 3 (complaint present and disturbing daily functioning).

19 OCP are evaluated using an extensive neuropsychological assessment covering multiple
20 cognitive domains and containing both traditional (e.g. Rey Complex Figure Test[18]) and
21 more ecologically valid tests (e.g. Rivermead Behavioural Memory Test[19]). See Table 1 for
22 an overview of all OCP tests used. In Spreen and Straus [20] and Lezak et al.[21] a detailed
23 description of each of the instrument we use is given.

1 Secondary outcomes include QoL, ADL functioning, and subjective stroke recovery.

2 Generic QoL is evaluated using the short version of the self-report World Health Organization
3 Quality of Life Questionnaire (WHOQOL-Bref)[22] (26 items) and, because we expect the
4 majority of our population to be elderly (> 60 years), the additional OLD module (WHOQOL-
5 OLD)[23] comprising 24 items. Whereas the first covers overall well-being on the domains
6 'physical', 'psychological', social relationships' and 'environment', the OLD module evaluates
7 aspects of life which are specific for the elderly, including: 'intimacy', 'sensory abilities',
8 'autonomy', 'activities in the past, present and future', 'social participation', and 'dying'.

9 Subjective recovery after stroke is determined by a single item from the Stroke Impact
10 Scale,[24] in which patients are asked to indicate on a scale ranging from 0 ('no recovery') to
11 100 ('full recovery') how much they feel they have recovered from their stroke.

12 ADL functioning is assessed in basic activities, including self-care and mobility, using
13 the Barthel Index [25] (10 items), and more complex activities like housekeeping, hobbies, and
14 employment, using the Frenchay Activities Index [26] (15 items).

15 All of the chosen instruments are (inter-)nationally frequently used in both research and
16 daily clinical practice dealing with stroke patients.

17

18 *Determinants*

19 Depending on the specific outcome considered, SCC, OCP, QoL, subjective recovery, and
20 ADL functioning are either dependent or independent variables. A wide range of possible
21 determinants are additionally taken into account, based on what is currently known from the
22 literature on SCC in the general and the stroke population. These include: demographic
23 variables, clinical characteristics (those related to stroke included), and health status; premorbid
24 status (i.e. cognitive decline, IQ, cognitive and emotional complaints); comorbid complaints

1
2
3
4 1 about mood (i.e. anxiety and depression), fatigue, and stress; personal factors (i.e. coping style,
5
6 2 personality traits, and SCC awareness), and the occurrence and impact of positive and/or
7
8 3 negative live events. See Table 2 for the specific variables assessed and instruments used.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Primary and secondary outcomes in the COMPAS study

Instrument		T0	T1	T2	T3	T4
Primary outcomes						
SCC	Cognitive Failures Questionnaire [16 17]		X	X	X	X
	Checklist for Cognitive and Emotional Consequences [5]		X	X	X	X
OCP [20 21]						
Global cognitive functioning	Mini-Mental State Examination		X		X	X
Visual perception and construction	Rey Complex Figure Test – copy trial		X		X	X
Mental speed / attention	Stroop Colour word test - card 1 and 2		X		X	X
	Digit Symbol-Coding		X		X	X
Episodic memory	Rivermead Behavioural Memory Test		X		X	X
	Rey Complex Figure Test - immediate and delayed recall trials		X		X	X
	Verbal Paired Associates		X		X	X
Working memory	Digit span Forward and Backward condition		X		X	X
Language	Boston Naming Test - short version		X		X	X
Executive functioning	Controlled Oral Word Association Test – FAS		X		X	X
	Category Fluency Test: animals and occupations		X		X	X
	Stroop Colour Word Test - card 3		X		X	X
	Rule Shift Cards		X		X	X
	Zoo Map		X		X	X

Fine motor dexterity	Purdue Pegboard		X	X	X
Secondary outcomes					
Quality of Life	World health Organization Quality of Life Questionnaire – short form [22]		X	X	X
	World health Organization Quality of Life Questionnaire – Old module [23]		X	X	X
ADL functioning					
Basic ADL	Barthel index [25]	P	X	X	X X
Instrumental ADL	Frenchay Activities Index [26]		X	X	X X
Subjective stroke recovery	Item 9 of Stroke Impact Scale [24]		P	P	P

ADL: Activities in Daily Life; C: control group only; OCP: objective cognitive performance; P: patient group only; SCC: subjective cognitive complaints; X: instrument used in both patients and controls.

Table 2. Determinants in the COMPAS-study

	Variable / instrument	T0	T1	T2	T3	T4
Demographic variables	Age, gender, education, marital status, living situation, residence, employment status, hand preference	P	X	X	X	X
Clinical characteristics						
Stroke specific	Life-time history of stroke, type, side, classification according to the Oxford Community Stroke Project [27], severity within 24 hours after admission using the National Institutes of Health Stroke Scale [28], treatment, post-stroke complications, length of hospital stay, discharge destination	P				
General	Vascular risk factors, comorbidity (Cumulative Illness Rating Scale [29]), (re-) admissions to hospital, medication use, current participation in rehabilitation therapy		X	X	X	X
Health status	12-Item Short Form Health Survey [30]		X		X	X
Premorbid status						
Cognitive decline	Informant Questionnaire on Cognitive Decline in the Elderly – short form [15]	P	C			
IQ estimation	Dutch version National Adult Reading Test [31]		X			
Cognitive complaints	Self-made item: “in the previous months (before your stroke), have you experienced cognitive complaints?”	P	C			
Depressive complaints	Self-made item: in the previous months (before your stroke), have you experienced depressive complaints?”	P	C			

1								
2								
3								
4								
5								
6	Anxiety complaints	Self-made item: in the previous months (before your stroke), have you experienced	P	C				
7		anxiety complaints?"						
8								
9	Current comorbid complaints							
10								
11	Depressive complaints	Hospital Anxiety and Depression Scale – subscale Depression [32]			X	X	X	X
12	Anxiety complaints	Hospital Anxiety and Depression Scale – subscale Anxiety [32]			X	X	X	X
13	Fatigue	Fatigue Assessment Scale [33]			X	X	X	X
14	Stress	Perceived Stress Scale, 4-item version [34]			X		X	X
15								
16	Personal factors				X		X	X
17								
18	Coping style	Utrecht Coping List – 15-item version [35]			X			
19	Personality trait - neuroticism	Eysenck Personality Questionnaire Revised Short Scale – subscale Neuroticism			X			
20		[36]						
21	Personality trait - extraversion	Eysenck Personality Questionnaire Revised Short Scale - Extraversion subscale			X			
22		[36]						
23	Type D	Type D scale-14 [37]			X			
24	Participants' awareness of SCC	Cognitive Failures Questionnaire completed by proxy			X	X	X	X
25		Checklist for Cognitive and Emotional Consequences completed by proxy			X	X	X	X
26	Life events	Self-made item concerning the presence and impact of a positive or negative life			X		X	X
27		event: "Last year, did something happen in your life which had a major impact on						
28		you? This may be something either pleasant or sad."						
29								
30								
31								
32								
33								
34								
35								
36								
37								
38	P: patient group only; SCC: subjective cognitive complaints; X: instrument used in both patients and controls.							
39								
40								
41								
42								
43								
44								
45								
46								
47								
48								
49								

1 **Planned statistical analyses**

2 Cross-sectional analyses will be used to evaluate group differences on each of the individual
3 time points (T1 to T4) and include: Chi-square test for categorical variables, the Mann-
4 Whitney *U* test for ordinal data, and the Student *t*-test or (multivariate) analysis of variances
5 ((M)ANOVA) for continuous dependent variables. Differences across the different time
6 points will furthermore be analyzed using multilevel analysis, which allows including all
7 available data (i.e. also those from participants with partly missing values).

8 The course of SCC over time (T1 to T4) will subsequently be evaluated using latent
9 class growth analysis. We will explore whether groups with different trajectories of SCC over
10 time can be distinguished and if so, what their characteristics are.

11 The predictive value of the determinants for the primary and secondary outcome
12 measures (i.e. SCC, OCP, QoL, subjective recovery, and ADL functioning) at T3 and T4 will
13 be determined using multivariate regression analysis. Potential predictors are defined as
14 variables with at least a marginally significant association ($p < 0.10$) with the outcome. Only
15 these variables will be included in the subsequent regression analyses to determine the most
16 important predictors. In general, effects with a two-tailed $p < 0.05$ are considered statistically
17 significant.

19 **Sample size and power calculation**

20 The sample size needed in the COMPAS study is calculated using the method for multilevel
21 analysis according to Twisk.[38] Based on a high intra-individual correlation across the
22 different time points ($\rho = 0.70$), an alpha level of 0.05, and power of 0.80, there are 180
23 participants per group needed to be able to detect a small difference (at least 0.2 standard
24 deviation) between the groups. We expect about 40% drop-outs during the two-year follow-

1
2
3
4 1 up period due to mortality, comorbidity or refusal to continue participation. Therefore, we
5
6 2 aim to include 300 participants at baseline in each group in order to end up with the 180 per
7
8 3 group needed.
9
10
11 4
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **1 ETHICS AND DISSEMINATION**

5
6 **2 Ethical considerations**

7
8 The COMPAS study is conducted in accordance with the “Helsinki Declaration”(Seoul
9
10 revision, 2008) and the “medical Research Involving Human Subjects Act”(WMO). The
11
12 study is non-invasive, imposes no risk on participants, and the protocol has been approved by
13
14 the medical ethical committees of all participating hospitals (i.e. St. Elisabeth and
15
16 TweeSteden Hospitals in Tilburg, and the Maxima Medical Centre in Veldhoven) and is
17
18 registered by the Central committee on Research Involving Human Subjects (number
19
20 NL31208.008.10). Written informed consent is furthermore obtained from all participants.
21
22
23

24
25
26 **11 Dissemination**

27
28 The results obtained will be disseminated to the scientific, medical and general public by
29
30 publication in national and international peer-reviewed journals, by presentation on
31
32 conferences, and meetings with clinicians dealing with stroke patients.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **DISCUSSION**

2 The COMPAS study is the first in which post-stroke SCC are systematically evaluated over
3 time, while a wide range of subjective and objective variables in patients and controls is taken
4 into account. Whereas numerous studies have measured post-stroke OCP, only a few have
5 also evaluated the patients' SCC. Whereas these complaints are found to be common among
6 stroke patients, knowledge about their risk factors, their course over time, differences with
7 the non-stroke population, and their predictive value for future functioning is practically non-
8 existent.

9 Strong elements of the COMPAS study are its prospective design with multiple
10 assessments during the first two years after stroke, and the extensive evaluations of both
11 subjective and objective variables which, based on the current literature, are potentially
12 relevant to SCC after stroke. This gives us the opportunity to determine a detailed risk profile
13 for experiencing post-stroke SCC. The instruments chosen are furthermore widely accepted
14 and frequently used in daily clinical practice dealing with stroke patients. Both traditional
15 neuropsychological and more ecologically valid tests (e.g. the Rivermead Behavioural
16 Memory Test) are used to evaluate OCP, making it possible to determine whether the
17 ecological validity of tests affects the association between SCC and OCP. Also, a healthy
18 control group is assessed at the same time points as the patients and will be used as a
19 reference group. This enables us to distinguish post-stroke SCC in their prevalence, profile
20 and time course from for example factors which are associated with ageing. A potential
21 limitation of the study is that the most serious affected stroke patients are unable to
22 participate, thereby reducing the possibility to generalize the results to the stroke population
23 as a whole. However, our study differs from those carried out to date in this field in that we

1
2
3
4 1 include a broad selection of stroke patients, not only first-ever strokes or patients discharged
5
6 2 home.

7
8 3 In conclusion, we feel that the COMPAS study has the potential to contribute to the
9
10 4 knowledge on post-stroke SCC. Due to ageing of the population and health care
11
12 5 improvements, the number of stroke survivors who will have to deal with post-stroke
13
14 6 impairment will increase in the future, and the social and economic burden will rise
15
16 7 accordingly.[39 40] Clinicians are frequently confronted with patients having SCC after their
17
18 8 stroke, but the meaning and relevance of these SCC has yet to be determined. We aim to
19
20 9 elucidate the possible risk factors, prognosis, and the predictive value of post-stroke SCC.

21
22 10 This information can subsequently be applied by clinicians in daily practice in order to more
23
24 11 accurately inform patients and their proxies and to treat SCC. Our data may also prove useful
25
26 12 in the future development of patient tailored intervention programmes to ultimately improve
27
28 13 individual stroke patient-centred care, which is the ultimate aim of the COMPAS study.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 Authors' contributions**

5
6 R.M., P.K, and M.R. conceptualized the study. M.S. and R.M. contributed to the procurement
7
8 of funding. M.R., R.M., and P.K. developed procedures for implementing the protocol. All
9
10 authors contributed to and have checked the final manuscript.
11
12

13
14
15 **6 Funding**

16
17 This study is financially supported by the Centre of Research on Psychology in Somatic
18
19 diseases (CoRPS) from Tilburg University, The Netherlands.
20
21

22
23
24
25
26 **11 Competing interests**

27
28 None declared.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lamb F, Anderson J, Saling M, et al. Predictors of subjective cognitive complaint in post-acute older adult stroke patients. *Arch Phys Med Rehabil* Published Online First: 22 March 2013. doi: 10.1016/j.apmr.2013.02.026.
2. Winkens I, Van Heugten CM, Fasotti L, et al. Reliability and validity of two new instruments for measuring aspects of mental slowness in the daily lives of stroke patients. *Neuropsychol Rehabil* 2009;**19**(1):64-85.
3. van Rijsbergen MW, Mark RE, de Kort PL, et al. Subjective cognitive complaints after stroke: a systematic review. *Journal of Stroke and Cerebrovasc Dis* Published Online First: 22 June 2013. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.003.
4. Duits A, Munnecom T, van Heugten C, et al. Cognitive complaints in the early phase after stroke are not indicative of cognitive impairment. *J Neurol Neurosurg Psychiatry* 2008;**79**(2):143-6.
5. van Heugten C, Rasquin S, Winkens I, et al. Checklist for cognitive and emotional consequences following stroke (CLCE-24): development, usability and quality of the self-report version. *Clin Neurol Neurosurg* 2007;**109**(3):257-62.
6. Wilz G, Barskova T. Predictors of psychological and somatic components of poststroke depression: a longitudinal study. *Top Stroke Rehabil* 2007;**14**(3):25-40.
7. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. *Int J Geriatr Psychiatry* 2000;**15**(11):983-91.
8. Reid LM, MacLullich AM. Subjective memory complaints and cognitive impairment in older people. *Dement Geriatr Cogn Disord* 2006;**22**(5-6):471-85.

- 1
2
3
4 1 9. Comijs HC, Deeg DJ, Dik MG, et al. Memory complaints; the association with psycho-
5
6 2 affective and health problems and the role of personality characteristics. A 6-year
7
8 3 follow-up study. *J Affect Disord* 2002;**72**(2):157-65.
9
10
11 4 10. Jorm AF, Butterworth P, Anstey KJ, et al. Memory complaints in a community sample
12
13 5 aged 60-64 years: associations with cognitive functioning, psychiatric symptoms,
14
15 6 medical conditions, APOE genotype, hippocampus and amygdala volumes, and
16
17 7 white-matter hyperintensities. *Psychol Med* 2004;**34**(8):1495-506.
18
19
20 8 11. Paradise MB, Glozier NS, Naismith SL, et al. Subjective memory complaints, vascular
21
22 9 risk factors and psychological distress in the middle-aged: a cross-sectional study.
23
24 10 *BMC Psychiatry* 2011;**11**:108.
25
26 11 12. Mol M, Carpay M, Ramakers I, et al. The effect of perceived forgetfulness on quality of
27
28 12 life in older adults; a qualitative review. *Int J Geriatr Psychiatry* 2007;**22**(5):393-400.
29
30
31 13 13. Berg A, Palomaki H, Lonnqvist J, et al. Depression among caregivers of stroke survivors.
32
33 14 *Stroke* 2005;**36**(3):639-43.
34
35 15 14. van Exel NJ, Koopmanschap MA, van den Berg B, et al. Burden of informal caregiving
36
37 16 for stroke patients. Identification of caregivers at risk of adverse health effects.
38
39 17 *Cerebrovasc Dis* 2005;**19**(1):11-7.
40
41
42 18 15. de Jonghe JF, Schmand B, Ooms ME, et al. [Abbreviated form of the Informant
43
44 19 Questionnaire on cognitive decline in the elderly]. *Tijdschr Gerontol Geriatr*
45
46 20 1997;**28**(5):224-9.
47
48
49 21 16. Broadbent DE, Cooper PF, FitzGerald P, et al. The Cognitive Failures Questionnaire
50
51 22 (CFQ) and its correlates. *Br J Clin Psychol* 1982;**21** (Pt 1):1-16.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 1 17. Ponds R, van Boxtel M, Jolles J. [The 'Cognitive Failure Questionnaire' as a measure of
5
6 2 subjective cognitive functioning]. *Tijdschrift voor neuropsychologie - diagnostiek,*
7
8 3 *behandeling en onderzoek* 2006;**1**(2):37-45.
- 10 4 18. Osterrieth PA. [The test of copying a complex figure: A contribution to the study of
11
12 5 perception and memory] *Archives de Psychologie* 1944;**30**:206-353.
- 14 6 19. Wilson B, Cockburn J, Baddeley A, et al. The development and validation of a test
15
16 7 battery for detecting and monitoring everyday memory problems. *J Clin Exp*
17
18 8 *Neuropsychol* 1989;**11**(6):855-70.
- 20 9 20. Spreen O, Strauss E. *A compendium of neuropsychological tests Administration, norms*
21
22 10 *and commentary*. 2nd ed. New York Oxford University Press 1998.
- 24 11 21. Lezak MD, Howieson DB, Loring DW, et al. *Neuropsychological Assessment*. 4th ed.
25
26 12 New York: Oxford, 2004.
- 28 13 22. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-
29
30 14 BREF quality of life assessment: Psychometric properties and results of the
31
32 15 international field trial. A Report from the WHOQOL Group. *Qual Life Res*
33
34 16 2004;**13**(2):299-310.
- 36 17 23. Power M, Quinn K, Schmidt S. Development of the WHOQOL-old module. *Qual Life*
37
38 18 *Res* 2005;**14**(10):2197-214.
- 40 19 24. Williams LS, Weinberger M, Harris LE, et al. Development of a stroke-specific quality of
41
42 20 life scale. *Stroke* 1999;**30**(7):1362-9.
- 44 21 25. de Haan R, Limburg M, Schuling J, et al. [Clinimetric evaluation of the Barthel Index, a
45
46 22 measure of limitations in activities of daily living]. *Ned Tijdschr Geneeskd*
47
48 23 1993;**137**(18):917-21.

- 1
2
3
4 1 26. Holbrook M, Skilbeck CE. An activities index for use with stroke patients. *Age Ageing*
5
6 2 1983;**12**(2):166-70.
7
8 3 27. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically
9
10 4 identifiable subtypes of cerebral infarction. *Lancet* 1991;**337**(8756):1521-6.
11
12 5 28. Brott T, Adams HP, Jr., Olinger CP, et al. Measurements of acute cerebral infarction: a
13
14 6 clinical examination scale. *Stroke* 1989;**20**(7):864-70.
15
16 7 29. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. *J Am Geriatr Soc*
17
18 8 1968;**16**(5):622-6.
19
20 9 30. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of
21
22 10 scales and preliminary tests of reliability and validity. *Med Care* 1996;**34**(3):220-33.
23
24 11 31. Schmand B, Bakker D, Saan R, et al. [The Dutch Adult Reading Test: A measure of
25
26 12 premorbid intelligence] *Tijdschrift Gerontologie Geriatrie* 1991;**22**:15-19.
27
28 13 32. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*
29
30 14 1983;**67**(6):361-70.
31
32 15 33. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated
33
34 16 fatigue measure: The Fatigue Assessment Scale. *J Psychosom Res* 2003;**54**(4):345-52.
35
36 17 34. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc*
37
38 18 *Behav* 1983;**24**(4):385-96.
39
40 19 35. Sanderman R, Ormel J. [The Utrecht Coping List (UCL): validity and reliability]. *Gedrag*
41
42 20 *Gezond* 1992;**20**(1):32-37.
43
44 21 36. Sanderman R, Arrindell WA, Ranchor A, et al. [*Measurement of personality traits using*
45
46 22 *the Eysenck Personality Questionnaire: a manual*]. Groningen: Noordelijk Centrum
47
48 23 voor Gezondheidsvraagstukken, Rijksuniversiteit Groningen, 1995.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 1 37. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type
5
6 2 D personality. *Psychosom Med* 2005;**67**(1):89-97.
7
8 3 38. Twisk JWR. *Applied Longitudinal Data Analysis for Epidemiology*. New York:
9 4 Cambridge University Press, 2003.
10
11 5 39. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. *Lancet* 2008;**371**(9624):1612-23.
12
13 6 40. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. *Lancet*
14
15 7 Neurol 2007;**6**(2):182-7.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60